Avidity Biosciences Inc [RNA] stock prices are up 8.74% to $33.83 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RNA shares have gain 12.62% over the last week, with a monthly amount glided 2.45%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $70. Previously, BMO Capital Markets started tracking the stock with Outperform rating on March 12, 2025, and set its price target to $72. On March 07, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $70 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $72 on December 20, 2024. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $67 as its price target on November 26, 2024. Goldman started tracking with a Buy rating for this stock on September 24, 2024, and assigned it a price target of $59. In a note dated August 28, 2024, Barclays initiated an Overweight rating and provided a target price of $63 on this stock.
The stock price of Avidity Biosciences Inc [RNA] has been fluctuating between $21.56 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $59 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $33.83 at the most recent close of the market. An investor can expect a potential return of 74.4% based on the average RNA price forecast.
Analyzing the RNA fundamentals
The Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.90M for trailing twelve months, representing a surge of 35.57%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -34.77%, Pretax Profit Margin comes in at -29.58%, and Net Profit Margin reading is -29.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.26 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.27 points at the first support level, and at 28.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.25, and for the 2nd resistance point, it is at 36.66.
Ratios To Look Out For
It’s worth pointing out that Avidity Biosciences Inc [NASDAQ:RNA]’s Current Ratio is 15.73. As well, the Quick Ratio is 15.73, while the Cash Ratio is 2.24. Considering the valuation of this stock, the price to sales ratio is 373.10, the price to book ratio is 2.85.
Transactions by insiders
Recent insider trading involved Flanagan W. Michael, Chief Scientific Officer, that happened on Mar 11 ’25 when 20000.0 shares were sold. Officer, WILLIAM MICHAEL FLANAGAN completed a deal on Mar 11 ’25 to buy 20000.0 shares. Meanwhile, Chief Program Officer Gallagher Kathleen P. sold 5875.0 shares on Mar 03 ’25.
